MedKoo Cat#: 563571 | Name: UTL-5g
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

UTL-5g is a novel potential chemoprotective agent, TNF-α inhibitor that reduces cisplatin-induced side effects including nephrotoxicity, hepatotoxicity and hematotoxicity. It lowers elevated levels of AST, ALT, creatinine, BUN, and TNF-α, increases the reduced platelet count in mice, and acts as a novel chemo- and radioprotective agent.

Chemical Structure

UTL-5g
UTL-5g
CAS#646530-37-2

Theoretical Analysis

MedKoo Cat#: 563571

Name: UTL-5g

CAS#: 646530-37-2

Chemical Formula: C11H8Cl2N2O2

Exact Mass: 269.9963

Molecular Weight: 271.09

Elemental Analysis: C, 48.74; H, 2.97; Cl, 26.15; N, 10.33; O, 11.80

Price and Availability

Size Price Availability Quantity
5mg USD 450.00 2 Weeks
10mg USD 750.00 2 Weeks
50mg USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
UTL-5g; UTL 5g; UTL5g;
IUPAC/Chemical Name
N-(2,4-Dichlorophenyl)-5-methyl-3-isoxazolecarboxamide
InChi Key
ULPKSWAQDCJLMN-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H8Cl2N2O2/c1-6-4-10(15-17-6)11(16)14-9-3-2-7(12)5-8(9)13/h2-5H,1H3,(H,14,16)
SMILES Code
O=C(C1=NOC(C)=C1)NC2=CC=C(Cl)C=C2Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 271.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Carruthers NJ, Stemmer PM, Chen B, Valeriote F, Gao X, Guatam SC, Shaw J. Phosphoproteome and transcription factor activity profiling identify actions of the anti-inflammatory agent UTL-5g in LPS stimulated RAW 264.7 cells including disrupting actin remodeling and STAT-3 activation. Eur J Pharmacol. 2017 Sep 15;811:66-73. doi: 10.1016/j.ejphar.2017.05.049. Epub 2017 May 31. PubMed PMID: 28576409; PubMed Central PMCID: PMC5581996. 2: Shaw J, Wiegand R, Wu J, Bao X, Valeriote F, Li J. A liquid chromatography with tandem mass spectrometry method for simultaneous determination of UTL-5g and its metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jun 1;991:92-8. doi: 10.1016/j.jchromb.2015.04.015. Epub 2015 Apr 18. PubMed PMID: 25955381. 3: Wu J, Shaw J, Dubaisi S, Valeriote F, Li J. In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo- and radioprotective agent. Drug Metab Dispos. 2014 Dec;42(12):2058-67. doi: 10.1124/dmd.114.060095. Epub 2014 Sep 23. PubMed PMID: 25249693; PubMed Central PMCID: PMC4244871. 4: Swartz K, Zhang Y, Valeriote F, Chen B, Shaw J. Using a simple HPLC approach to identify the enzymatic products of UTL-5g, a small molecule TNF-α inhibitor, from porcine esterase and from rabbit esterase. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 1;940:1-6. doi: 10.1016/j.jchromb.2013.09.021. Epub 2013 Sep 23. PubMed PMID: 24126042; PubMed Central PMCID: PMC3830453. 5: Song Y, Zhang Y, Lee AR, Huang WH, Chen B, Palfey B, Shaw J. Comparison of two molecular scaffolds, 5-methylisoxazole-3-carboxamide and 5-methylisoxazole-4-carboxamide. Curr Pharm Des. 2014;20(1):146-52. Review. PubMed PMID: 23944378. 6: Shaw J, Media J, Chen B, Valeriote F. The small-molecule TNF-α inhibitor, UTL-5g, delays deaths and increases survival rates for mice treated with high doses of cisplatin. Cancer Chemother Pharmacol. 2013 Sep;72(3):703-7. doi: 10.1007/s00280-013-2236-4. Epub 2013 Jul 24. PubMed PMID: 23881213; PubMed Central PMCID: PMC3809999. 7: Shaw J, Chen B, Huang WH, Lee AR, Media J, Valeriote FA. The small-molecule TNF-alpha modulator, UTL-5g, reduces side effects induced by cisplatin and enhances the therapeutic effect of cisplatin in vivo. J Exp Ther Oncol. 2011;9(2):129-37. PubMed PMID: 21699020.